Table 3.

AEs during patiromer treatment through follow-up

Number of patients, %	Patiromer treatment group		Total (n = 113)
	without food (n = 57)	with food (n = 56)
Patients with ≥1 AEs	24 (42.1)	27 (48.2)	51 (45.1)
Most common AEs*
Diarrhea	3 (5.3)	3 (5.4)	6 (5.3)
Increased creatine phosphokinase	1 (1.8)	3 (5.4)	4 (3.5)
Constipation	2 (3.5)	2 (3.6)	4 (3.5)
Anemia	3 (5.3)	0 (0)	3 (2.7)
Headache	0 (0)	3 (5.4)	3 (2.7)
Urinary tract infection	1 (1.8)	2 (3.6)	3 (2.7)
Patients with ≥1 treatment-related AEs	6 (10.5)	7 (12.5)	13 (11.5)
Most common treatment-related AEs*
Diarrhea	1 (1.8)	2 (3.6)	3 (2.7)
Constipation	2 (3.5)	1 (1.8)	3 (2.7)
Discontinuations due to AEs	2 (3.5)	1 (1.8)	3 (2.7)
Patients with ≥1 serious AEs†	4 (7.0)	1 (1.8)	5 (4.4)
Deaths†	1 (1.8)	0	1 (0.9)
Prespecified laboratory values of interest
Serum K+ <3.5 mEq/L	0 (0)	0 (0)	0 (0)
Serum Mg2+ <1.4 mg/dL‡	3 (5.4)	2 (3.6)	5 (4.5)

AEs, adverse events; K⁺, potassium; Mg²⁺, magnesium.

^*Occurring in 3 or more patients overall.

^†None considered related to patiromer in the judgment of the investigator.

^‡Mg²⁺ levels were 1.2–1.3 mg/dL and not accompanied by symptoms.